What would change my mind about repair peptides: a specific answer — one year on

What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below.

Documentation question rather than a pharmacological one, but about this compound specifically.

What should a certificate for this actually carry, given its structure? I suspect the answer differs from the generic advice, and I would rather ask than assume the generic advice transfers.

Thank you for the correction. I would rather find out here than later.

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

I have kept the units in throughout, for the obvious reason.

Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.

Not the answer, but possibly the question that gets there.

The opening post and I disagree about the size of the effect, not about the direction.

What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.

Taking post #5 at face value and following it one step further.

The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.

That is a description of practice, not a recommendation of it.

Short peptides like these are chromatographically simple, so a purity result is comparatively easy to obtain and comparatively easy to make look good on a lazy gradient. Ask for the method.

Worth one more sentence than it usually gets.

The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.

Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.

Written from notes rather than memory, which is why the numbers are specific.

Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.

The interesting part of this is the exception, and I do not understand the exception.

Reading rather than contributing, but this is the most useful thread I have found on it.

Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.

The variance between people here is larger than the effect being discussed.

Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.

Answering the question post #12 raises rather than the one it answers.

Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.